Epidemiology and natural history of hepatitis B

[1]  Erwin Sablon,et al.  Advances in Molecular Diagnosis of HBV Infection and Drug Resistance , 2005, International journal of medical sciences.

[2]  J. Stockman,et al.  Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B , 2007 .

[3]  G. Fattovich.  Natural history of hepatitis B. , 2003, Journal of hepatology.

[4]  F. Zoulim.  Combination of nucleoside analogues in the treatment of chronic hepatitis B virus infection: lesson from experimental models. , 2005, The Journal of antimicrobial chemotherapy.

[5]  S. Locarnini,et al.  Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? , 2004, Gastroenterology.

[6]  J. Hoofnagle,et al.  Management of hepatitis B: Summary of a clinical research workshop , 2007, Hepatology.

[7]  S. Locarnini,et al.  Cellular and virological mechanisms of HBV drug resistance. , 2006, Journal of hepatology.

[8]  R. J. Colonno,et al.  Efficacies of Entecavir against Lamivudine-Resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro , 2002, Antimicrobial Agents and Chemotherapy.

[9]  Pietro Andreone,et al.  Clinical outcome of HBeAg‐negative chronic hepatitis B in relation to virological response to lamivudine , 2004, Hepatology.

[10]  Y. Shiratori,et al.  Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. , 1999, The Journal of clinical investigation.

[11]  Oliver N Keene,et al.  Lamivudine for patients with chronic hepatitis B and advanced liver disease. , 2004, The New England journal of medicine.

[12]  E. Keeffe,et al.  Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. , 2007, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  E. Keeffe,et al.  Management of Antiviral Resistance in Patients with Chronic Hepatitis B , 2004, Antiviral therapy.

[14]  Y. Liaw,et al.  No Benefit to Continue Lamivudine Therapy after Emergence of Ymdd Mutations , 2004, Antiviral therapy.

[15]  Yoshiyuki Suzuki,et al.  Interferon for treatment of breakthrough infection with hepatitis B virus mutants developing during long-term lamivudine therapy , 2002, Journal of Gastroenterology.

[16]  S. Locarnini.  Molecular virology and the development of resistant mutants: implications for therapy. , 2005, Seminars in liver disease.

[17]  M. Colombo,et al.  Long‐Term suppression of hepatitis B e antigen‐negative chronic hepatitis B by 24‐month interferon therapy , 2003, Hepatology.

[18]  S. Hadziyannis,et al.  The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. , 2001, Journal of hepatology.

[19]  F. Zoulim.  Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. , 2004, Antiviral research.

[20]  Angeline Bartholomeusz,et al.  Antiviral drug‐resistant HBV: Standardization of nomenclature and assays and recommendations for management , 2007, Hepatology.

[21]  P. Lampertico,et al.  Adefovir rapidly suppresses hepatitis B in HBeAg‐negative patients developing genotypic resistance to lamivudine , 2005, Hepatology.

[22]  M. Buti,et al.  Peginterferon alpha‐2b is safe and effective in HBeAg‐positive chronic hepatitis B patients with advanced fibrosis , 2007, Hepatology.

[23]  M. Brunetto,et al.  Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. , 2002, Journal of hepatology.

[24]  D. Glebe.  Recent advances in hepatitis B virus research: a German point of view. , 2007, World journal of gastroenterology.

[25]  F. Zoulim.  Entecavir: a new treatment option for chronic hepatitis B. , 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.